Veracyte (VCYT) Stock Price, News & Analysis

Company Overview

Veracyte, Inc. is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules. In addition, Veracyte offers the Percepta Genomic Sequencing Classifier for patients with lung nodules, as well as the Envisia Genomic Classifier for patients with suspected interstitial lung disease. These tests leverage RNA sequencing and advanced bioinformatics to deliver clinically actionable results, enabling more precise risk stratification and management of patients.

Veracyte operates certified laboratories in South San Francisco and Europe, serving a broad network of endocrinologists, pulmonologists and pathologists across the United States, Canada and selected European markets. The company collaborates with healthcare organizations and specialty groups to integrate its tests into diagnostic workflows, supporting evidence-based medicine and cost-effective care. Veracyte’s commercial operations are supported by a field sales force, partnerships with reference laboratories and direct engagement with key opinion leaders in oncology and pulmonary medicine.

Under the leadership of CEO Bonnie H. Anderson, Veracyte has pursued strategic growth initiatives, including the expansion of its test menu and development of new molecular classifiers. The company’s management team combines expertise in genomics, diagnostic development and commercial operations, positioning Veracyte to advance its pipeline and capitalize on emerging opportunities in precision diagnostics. By continuing to innovate in genomic science and build strategic partnerships, Veracyte aims to expand access to its tests and further enhance diagnostic accuracy worldwide.

Key Stats

• Today's Range: $57.06 to $59.19
• 50-Day Range: $38.25 to $60.49
• 52-Week Range: $22.61 to $60.91
• Volume: 2.01 million shs
• Average Volume: 1.04 million shs
• Market Capitalization: $4.72 billion
• P/E Ratio: 54.25
• Dividend Yield: N/A
• Price Target: $55.88
• Consensus Rating: Moderate Buy

Veracyte Stock Analysis - MarketRank™

Veracyte scored higher than 49% of companies evaluated by MarketBeat, and ranked 535th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 5 buy ratings, 3 hold ratings, and 1 sell rating.

Downside Risk

Veracyte has a consensus price target of $55.88, representing about 5.5% downside from its current price of $59.13.

Amount of Analyst Coverage

Veracyte has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 11.72%

Earnings Growth

Earnings for Veracyte are expected to grow by 11.72% in the coming year, from $1.28 to $1.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veracyte is 54.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.10.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veracyte is 54.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.25.

Price to Book Value per Share Ratio

Veracyte has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.54% of the float of Veracyte has been sold short.

Short Interest Ratio / Days to Cover

Veracyte has a short interest ratio ("days to cover") of 3.79, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Veracyte has recently decreased by 20.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veracyte does not currently pay a dividend.

Dividend Growth

Veracyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.69

News Sentiment

Veracyte has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Veracyte this week, compared to 4 articles on an average week.

Search Interest

14 people have searched for VCYT on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

7 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,079,058.00 in company stock.

Percentage Held by Insiders

1.60% of the stock of Veracyte is held by insiders.

Percentage Held by Institutions

Veracyte has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 7/17/2026
• Next Earnings (Confirmed): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:VCYT
• CIK: 1384101
• Web: www.veracyte.com
• Phone: (650) 243-6300
• Fax: 650-243-6301
• Employees: 790
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Veracyte: $55.88
• High Price Target: $66.00
• Low Price Target: $45.00
• Potential Upside/Downside: -5.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.09
• Trailing P/E Ratio: 54.25
• Forward P/E Ratio: 46.20
• P/E Growth: N/A
• Net Income: $66.35 million
• Net Margins: 16.25%
• Pretax Margin: 16.75%
• Return on Equity: 9.07%
• Return on Assets: 8.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.31
• Quick Ratio: 8.92

Sales & Book Value

• Annual Sales: $517.15 million
• Price / Sales: 9.12
• Cash Flow: $1.48 per share
• Price / Cash Flow: 39.95
• Book Value: $16.57 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 79,790,000
• Free Float: 78,516,000
• Market Cap: $4.72 billion
• Optionable: Optionable
• Beta: 1.93